TSVT צמיחת רווחי EPS רבעונית 2seventy bio
2seventy bio, Inc. (TSVT) attracts top engineers through innovations in CAR-T therapy, offering them autonomy and RSUs. Quarterly EPS growth illustrates the profitability trend, where this metric equals 100.80. However, trade wars and sanctions are hindering the global exchange of medical technologies. The business is currently focusing on the market rollout of Abecma and the optimization of its scientific portfolio to combat oncology.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%9E%D7%95%D7%A0%D7%97%D7%99%D7%9D%20%D7%A9%D7%A0%D7%AA%D7%99%D7%99%D7%9D%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_TSVT_-_2seventy-bio-Inc._-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "2seventybio.com (TSVT): צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים מ-04.07.2022 עד 24.05.2025 | 👁️GURU.Markets👁️")
2seventy bio, Inc (TSVT) - פילוחי מדדים ודוחות פיננסיים
The specifics of 2seventy bio, Inc. (TSVT) gene therapy amid geopolitical risks and logistical disruptions make the quarterly EPS growth rate a key indicator of the business's operational resilience. This metric measures the rate of change in net income per share relative to the previous quarter, allowing investors to assess the actual efficiency of asset capitalization and the company's long-term ability to generate income.
